Rates of severe disease low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies
New York City First to Offer Paxlovid at COVID-19 Testing Sites
‘Test-to-Treat’ program is part of federal and city efforts to catch and treat infections early and be ready for new waves of the pandemic
Fauci Has ‘Rebound’ COVID After Paxlovid Treatment
However, director of the NIAID says drug kept him out of the hospital
SARS-CoV-2-Linked Hospitalization, ED Encounters Rare After Paxlovid
<1 percent of patients to whom Paxlovid was dispensed for mild-to-moderate COVID-19 had hospitalization or ED encounter
Study Compares Baricitinib to Dexamethasone for COVID-19
Baricitinib plus remdesivir shows similar efficacy but better safety profile than dexamethasone plus remdesivir in hospitalized adults
Rebound of COVID-19 Symptoms Rare After Nirmatrelvir/Ritonavir Treatment
Only 0.8 percent of 483 patients with mild-to-moderate SARS-CoV-2 at high risk for severe disease progression had rebound
More Clinical Benefits of Molnupiravir ID’d in COVID-19
Compared with placebo, normalization of C-reactive protein and oxygen saturation faster, with improvements seen on day 3 of treatment
Disparities in Filled Buprenorphine Rx Worse During Pandemic
At pandemic outset, significant decreases in buprenorphine prescription fills seen for Black, Hispanic patients, but not White patients
During Pandemic, Growth of Clinicians With X-Waivers for Buprenorphine Prescribing Slowed
Survey of 126 clinicians helps pinpoint barriers to obtaining waivers, prescribing buprenorphine
Rare Cases of COVID-19 Relapse Seen With Pfizer Pill
Reports of symptoms returning in patients several days after completing the five-day regimen of Paxlovid